These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2583918)

  • 21. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss.
    Yen TT; Fuller RW
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):177S-180S. PubMed ID: 1728830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An assessment of the thermogenic effects of fluoxetine in obese subjects.
    Stinson JC; Murphy CM; Andrews JF; Tomkin GH
    Int J Obes Relat Metab Disord; 1992 May; 16(5):391-5. PubMed ID: 1319975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder.
    Devlin MJ; Goldfein JA; Petkova E; Jiang H; Raizman PS; Wolk S; Mayer L; Carino J; Bellace D; Kamenetz C; Dobrow I; Walsh BT
    Obes Res; 2005 Jun; 13(6):1077-88. PubMed ID: 15976151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoxetine increases resting energy expenditure and basal body temperature in humans.
    Bross R; Hoffer LJ
    Am J Clin Nutr; 1995 May; 61(5):1020-5. PubMed ID: 7733022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of fluoxetine and placebo in the treatment of obesity.
    Fernández-Soto ML; González-Jiménez A; Barredo-Acedo F; Luna del Castillo JD; Escobar-Jiménez F
    Ann Nutr Metab; 1995; 39(3):159-63. PubMed ID: 7486842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluoxetine treatment of the obese diabetic.
    Gray DS; Fujioka K; Devine W; Bray GA
    Int J Obes Relat Metab Disord; 1992 Mar; 16(3):193-8. PubMed ID: 1317828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects.
    Astrup A; Greenway FL; Ling W; Pedicone L; Lachowicz J; Strader CD; Kwan R;
    Obesity (Silver Spring); 2007 Jul; 15(7):1717-31. PubMed ID: 17636090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
    Max MB; Lynch SA; Muir J; Shoaf SE; Smoller B; Dubner R
    N Engl J Med; 1992 May; 326(19):1250-6. PubMed ID: 1560801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoxetine-induced weight loss in overweight non-depressed humans.
    Ferguson JM; Feighner JP
    Int J Obes; 1987; 11 Suppl 3():163-70. PubMed ID: 3501992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoxetine-maintained obese humans: effect on food intake and body weight.
    Ward AS; Comer SD; Haney M; Fischman MW; Foltin RW
    Physiol Behav; 1999 Jul; 66(5):815-21. PubMed ID: 10405110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial.
    Pedrinola F; Sztejnsznajd C; Lima N; Halpern A; Medeiros-Neto G
    Obes Res; 1996 Nov; 4(6):549-54. PubMed ID: 8946439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperphagia and weight loss during fluoxetine treatment.
    Fichtner CG; Braun BG
    Ann Pharmacother; 1994 Dec; 28(12):1350-2. PubMed ID: 7696724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet.
    Huang CC; Chian CY; Lin JD
    Changgeng Yi Xue Za Zhi; 1998 Mar; 21(1):50-6. PubMed ID: 9607264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers.
    Wurtman J; Wurtman R; Berry E; Gleason R; Goldberg H; McDermott J; Kahne M; Tsay R
    Neuropsychopharmacology; 1993 Nov; 9(3):201-10. PubMed ID: 8280344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success.
    Goldstein DJ; Rampey AH; Roback PJ; Wilson MG; Hamilton SH; Sayler ME; Tollefson GD
    Obes Res; 1995 Nov; 3 Suppl 4():481S-490S. PubMed ID: 8697047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients.
    Achiron A; Barak Y; Noy S; Pinhas-Hamiel O
    Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):111-3. PubMed ID: 10082236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.